Trial Profile

A First-in-Human Study of [18F]EKZ-001 in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluorine-18 Bavarostat (Primary)
Indications Alzheimer's disease; Amyotrophic lateral sclerosis
Focus Diagnostic use; First in man; Pharmacokinetics
Sponsors Eikonizo Therapeutics

Most Recent Events

13 Jul 2020 New trial record
08 Jul 2020 According to an Eikonizo Therapeutics media release, the study was approved by the independent Ethics Committee of the University Hospitals of KU Leuven and was performed in accordance with the World Medical Association Declaration of Helsinki.
08 Jul 2020 According to an Eikonizo Therapeutics media release, the company plans to use [18F]EKZ-001 PET to confirm and quantify brain HDAC6 target engagement by Eikonizo's drug candidates in therapeutic clinical trials.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com